Elizabeth R. Plimack

Elizabeth R. Plimack

Auto-generated profile, based on publicly available information

Elizabeth R. Plimack

Fox Chase Cancer Center

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2018 in Science
Verified
Journal Article
Closed access
PDF file
RCRazvan Cristescu
Razvan Cristescu
RMRobin Mogg
Robin Mogg
MAMark Ayers
Mark Ayers
AAAndrew Albright
Andrew Albright
EMErin Murphy
Erin Murphy
DKDavid Kaufman
David Kaufman
Mining immunotherapy clinical trials: Clinical trial data can provide a wealth of information about how drugs work. Yet such information often belongs to pharmaceutical companies and is rarely accessible to the scientific community at large. Cristescu et al. provide exploratory analysis of a cancer genomics dataset, collected from four separate clinical trials of Merck's PD-1 immunotherapy drug, pembrolizumab. This informative public resource examines more than 300 patient samples representing 22 different tumor types. Two widely used signatures that currently predict immunotherapy response are tumor mutational burden and a “hot” T cell–inflamed microenvironment. The study analyzed these two proposed biomarkers in combination to see what predictive clinical utility they may hold. Science , this issue p. eaar3593

1 December 2015 in European Urology
Verified
Journal Article
Closed access
EPElizabeth R. Plimack
Elizabeth R. Plimack
RDRoland L. Dunbrack
Roland L. Dunbrack
TBTimothy A. Brennan
Timothy A. Brennan
MAMark D. Andrake
Mark D. Andrake
YZYan Zhou
Yan Zhou
EREric A. Ross
Eric A. Ross

22 April 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TCToni K. Choueiri
Toni K. Choueiri
TBTodd M. Bauer
Todd M. Bauer
KPKyriakos P. Papadopoulos
Kyriakos P. Papadopoulos
EPElizabeth R. Plimack
Elizabeth R. Plimack
JMJaime R. Merchan
Jaime R. Merchan
EJEric Jonasch
Eric Jonasch

1 February 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
EPElizabeth R Plimack
Elizabeth R Plimack
JBJoaquim Bellmunt
Joaquim Bellmunt
SGShilpa Gupta
Shilpa Gupta
RBRaanan Berger
Raanan Berger
LCLaura Q M Chow
Laura Q M Chow
POPeter H O'DOnnell
Peter H O'DOnnell

20 June 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EPElizabeth R. Plimack
Elizabeth R. Plimack
JHJean H. Hoffman-Censits
Jean H. Hoffman-Censits
RVRosalia Viterbo
Rosalia Viterbo
ETEdouard J. Trabulsi
Edouard J. Trabulsi
EREric A. Ross
Eric A. Ross
GHGary R. Hudes
Gary R. Hudes
Purpose: Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC); however, it is infrequently adopted in practice because of concerns regarding toxicity and delay to cystectomy. We hypothesized that three cycles of neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) would be safe, shorten the time to surgery, and yield similar pathologic complete response (pT0) rates compared with historical controls. Patients and Methods: Patients with cT2-T4a and N0-N1 MIBC were eligible and received three cycles of AMVAC with pegfilgrastim followed by radical cystectomy with lymph node dissection. The primary end point was pT0 rate. Telomere length (TL) and p53 mutation status were correlated with response and toxicity. Results: Forty-four patients were accrued; 60% had stage III to IV disease; median age was 64 years. Forty patients were evaluable for response, with 15 (38%; 95% CI, 23% to 53%) showing pT0 at cystectomy, meeting the primary end point of the study. Another six patients (14%) were downstaged to non–muscle invasive disease. Most (82%) experienced only grade 1 to 2 treatment-related toxicities. There were no grade 3 or 4 renal toxicities and no treatment-related deaths. One patient developed metastases and thus did not undergo cystectomy; all others (n = 43) proceeded to cystectomy within 8 weeks after last chemotherapy administration. Median time from start of chemotherapy to cystectomy was 9.7 weeks. TL and p53 mutation did not predict response or toxicity. Conclusion: AMVAC is well tolerated and results in similar pT0 rates with 6 weeks of treatment compared with standard 12-week regimens. Further analysis is ongoing to ascertain whether molecular alterations in tumor samples can predict response to chemotherapy.

25 July 2023 in European Urology
Verified
Journal Article
Closed access
EPElizabeth R. Plimack
Elizabeth R. Plimack
TPThomas Powles
Thomas Powles
VSViktor Stus
Viktor Stus
RGRustem Gafanov
Rustem Gafanov
DNDmitry Nosov
Dmitry Nosov
BRBrian I. Rini
Brian I. Rini